Skip to content

Efficacy and Safety of Infrahepatic Inferior Vena Cava Clamping under controlled central venous pressure for Reducing Blood Loss During Hepatectomy : A Randomized Controlled Trial

Efficacy and Safety of Infrahepatic Inferior Vena Cava Clamping under controlled central venous pressure for Reducing Blood Loss During Hepatectomy : A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20160309001
Enrollment
120
Registered
2016-03-09
Start date
2016-03-07
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients scheduled for elective hepatectomy due to any reason at Department of surgery &#44

Interventions

The Partial infrahepatic IVC calmping group &#44
Infrahepatic IVC will be partially clamped just before starting hepatic resetion without any anesthiological technique to reduce CVP . The CVP will be monitored without controlling ,The None infrahe
Venodilators administration(Nitroglycerine) and Diuretics administration&#44
aiming to keep CVP level below 5 cmH2O
Active Comparator Procedure/Surgery,Active Comparator Procedure/Surgery
Partial infrahepatic IVC clamping,None infrahepatic IVC clamping

Sponsors

Research Fund from Faculty of madicine , Chiang Mai University
Lead Sponsor
Research Fund from Faculty of madicine &#44
Collaborator
Chiang Mai University
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: -Age ≥ 18 years -Elective hepatic resection due to any reason -American Society of Anesthesiologists (ASA) score I to III -Written informed consent

Exclusion criteria

Exclusion criteria: •Presence of medical conditions putting the individual patient at increased risk for not tolerating hepatic resection - Liver cirrhosis (Child-Pugh B or C) - Coagulopathy •Technical impossibility of hepatic resection •Presence of medical conditions putting the individual patient at increased risk of not tolerating at least one of this trial's study interventions: - Severe heart disease (e.g. severe coronary artery disease requiring intervention, cardiac insufficiency NYHA stage IV) - Pulmonary hypertension - Renal insufficiency (serum creatinine > 2 mg/dl or > 177 μmol/l; conversion factor 88.4 or requiring dialysis) - Uncorrected electrolyte imbalance •Atrial fibrillation •For female patients: pregnancy or lactation •Participation in other clinical trials or observation period of competing trials interfering with the endpoints of this trial •Suspected lack of compliance •Impaired mental status or language problems •Refusal to take part in the study

Design outcomes

Primary

MeasureTime frame
Intra-operative blood loss Intraoperative period ml/The amount of blood loss is measured from the amount of blood collected in the suction containers

Secondary

MeasureTime frame
CVP Intraoperative period cmH2O / The CVP wasmeasure via Central venous catherter by anesthesiologist,Intraoperative hemodynamic status-Heart rate and MAP Intraoperative period beats per min and mmHg,Operation time Intraoperative period minute,Intraoperative blood and blood component transfusion Intraoperative period unit,Post operative blood and blood component transfusion Postoperative period unit,Postoperative hospitalization Postoperative period until the patient was discharged from hospital days,Complication Intraoperativeand post operative period The complication will be recorded both intraoperation and postoperation,such as Pulmonary air emboli

Countries

Thailand

Contacts

Public ContactKarnpichamonch Suwannikom

Department of surgery , Maharaj Nakorn Chiang Mai hospital , Faculty of medicine , Chiang Mai univer

mezzypl@yahoo.com+66817461122

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026